Psychopharmacological treatment of personality disorders - Risks and chances

Psychiatria Danubina

Volumn 11, Issue 3-4, 1999, Pages 131-139

  Dose, Matthias ^a  

^a NONE

Author keywords

Affective instability; Antidepressants; Anxiety inhibition; Benzodiazepines; Cognitive perceptual disorganization; Dimensional defined symptom domains; Impulsive behavioural dysregulation; Mood stabilizers; Neuroleptics; Personality disorders

Indexed keywords

EID: 28444455714     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. American Psychiatric Association: Diagnostisches und Statistisches Manual Psychischer Störungen, DSM-III. Deutsche Bearbeitung und Einführung von K. Koehler und H. Saß. Beltz, Weinheim, Basel, 1984
2. Andreasen NC, Black DW: Lehrbuch Psychiatrie. Beltz, Weinheim, Basel, 1993
3. Androlunis PA, Gluech BC, Stroebel CF: Borderline personality disorder subcategories. J Nerv Ment Dis 1982;170:670-679
4. Black DW, Bell S, Hulbert J et al.: The importance of Axis II in patients with major depression. J Affect Dis 1988; 14:115-122
5. Coccaro EF, Siever LJ, Klar HM et al.: Serotonoergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behgavior. Arch Gen Psychiatry 1990; 47: 124-136
6. Cowdry RW, GardnerDL: Pharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 1988; 45: 111-119
7. Delay J, Deniker P, Had JM: Traitement des etats d' excitation et d' agitation par une methode medicamenteuse derivee de l' hibernotherapie. Ann Med Psychol 1954; 110: 267-273.
8. Diagnosenschlüssel und Glossar psychiatrischer Krankheiten: dt. Ausgabe d. internat. Klassifikation d. Krankheiten d. WHO. R Degkwitz, H Heichen, W Mombour (Hrsg im Auftrag der DGPN). Springer, Berlin, Heidelberg, 1980
9. Diagnostisches und Statistisches Manual psychischer Störungen (DSM-IV). H. Saß, HU Wittchen, M Zaudig (Deutsche Bearbeitung und Einführung). Hogrefe, Göttingen, Bern, Toronto, Seattle, 1996
10. Dose M, Apelt S, Emrich HM: Carbamazepine as an adjunct of antiposychotic therapy. Psychiatry Res 1987; 22: 203-204
11. Gaind R, Jacoby R: Benzodiazepines causing aggression. In: Gaind R, Huson GL (eds) : Current themes in psychiatry. London, McMillan Publishing Co, 1978; vol 1:371-379
12. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO: Borderline and schizotypal personality disorders treated with low dose Thithixene vs placebo. Arch Gen Psychiatry 1986; 43: 680-686
13. Gunderson JG: Pharmacotherapy for patients with borderline personality disorder. Arch Gen Psychiatry 1986;43:698-700
14. Jann MW, Ereshefsky L, Sakland SR et al.: Effects of carbamazepine on haloperidol levels. J Clin Psychopharmacol 1985; 5: 106-109
15. Kernberg O: The treatment of patients with borderline personality organisation. Int J Psychoanalysis, 1968; 49: 600-619
16. Klein DF, Fink M: Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962; 119: 432-438
17. Lambert PA: Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacctamide). In: HM Emrich, T Okuma, AA Müller (eds) Anticonvulsants in affective disorders. Elsevier, Amsterdam, 1984; 33-44
18. Markovitz PJ, Calabrese JR, Schultz SC et al.: Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991.; 148: 1064-1067
19. Rampling D: Agression-a paradoxical response to tricyclic antidepressants. Am J Psychiatry 1978; 135: 117-118
20. Rifkin A, Quitkin F, Carillo C. et al.: Lithkum carbonate in emotionally unstable character disorder. Arch Gen Psychiatry 1972; 27: 519-523
21. Salzman C, Kochansky GE, Shader RI, Porrino LJ, Harmatz JS, Swett CP Jr: Chlordiazepoxise-induced hostility in a small group setting. Arch Gen Psychiatry 1974; 31: 401-405
22. Salzman C, Wolfson AN, Schatzberg SC et al.: Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15: 23-29
23. Schmideberg M: The borderline patient. In: American Handbook of Psychiatry (ed. S Arieti) vol 1, Basic Books, New York, 1959; 398-416
24. Sheard MH, Marini JL, Bridges CL et al.: The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133: 1409-1413
25. Siever LJ, Davis KL: A psychobiological perspective on the personality disorders. Am J Psychiatry 1997; 148: 1647-1658
26. Soloff PH, George A, Nathan RS et al.: Paradoxical effects of amitryptiline on borderline patients. Am J Psychiatry 1986; 143: 1603-1605
27. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM: Progress in pharmacotherapy of borderline disorders. Arch Gen Psychiatry 1986; 43:691-697
28. Soloff PH: Pharmacotherapy of borderline disorders. Compr Psychiatry 1981 ; 43: 691 -697
29. Stein G: Drug treatment of the personality disorders. Br J Psychiat 1992; 161: 167-184
30. Stone MH: Analytically orientated psychotherapy in schizotypal and borderline patients: at the border of treatability. Yale J Biol Med 1985; 58: 275-288
31. Valzelli L: Psychobiology of aggression and violence. New York, Raven Press, 1991
32. Weltgesundheitsorganisation: Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F), klinisch-diagnostische Leitlinien. H Dilling, W Mombour, MH Schmidt (Hrsg) Huber, Bern, Göttingen, Toronto, 1991
33. Wilcox JA: Divalproex sodium as a treatment for borderline personality disorder. Am J Psychiatry 1995;7:33-37
34. Winkleman NW: The use of neuroleptic drugs in the treatment of non-psychotic patients. In: Rational Psychopharmacotherapy and the Right to Treatment (ed. F Ayd) Baltimore: Ayd Medical Communications; 1975; 161
35. Zananarini MC, Frankenburg FR, Gunderson JC: Pharmacotherapy of borderline outpatients. Compr Psychiatry 1988; 29: 372-378